Pantoprazole

Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) [1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) [3][4].

Product Specifications

CAS Number

[102625-70-7]

Product Name Alternative

BY1023; SKF96022

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Apoptosis; Autophagy; Bacterial; Proton Pump

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Autophagy; Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pantoprazole.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(C1=NC2=CC=C(OC(F)F)C=C2N1)CC3=NC=CC(OC)=C3OC

Molecular Formula

C16H15F2N3O4S

Molecular Weight

383.37

Precautions

H315, H319, H320

References & Citations

[1]Krupa J Patel, et al. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013 Dec 15;19 (24) :6766-76.|[2]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35 (1) :1322-1330.|[3]W Beil, et al. Pantoprazole: a novel H+/K (+) -ATPase inhibitor with an improved pH stability. Eur J Pharmacol. 1992 Aug 6;218 (2-3) :265-71.|[4]K Takeuchi, et al. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14 (3) :251-7.